Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | HTT | P42858 | 8/20 | 0.58 |
| ▸ | MITF | O75030 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17347507 | 0.85 | MAPT (0.54) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL788257 | 0.85 | HTT (0.54) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL4872849 | 0.85 | MAPT (0.50) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL23634773 | 0.85 | MAPT (0.50) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL12832961 | 0.80 | MAPT (0.60) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL10968449 | 0.80 | MAPT (0.61) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL10961504 | 0.75 | PRMT1 (0.61) | MAPTHTTMITFKDM4ELMNA | |
| SCHEMBL14027291 | 0.74 | HTT (0.68) | MAPTHTTLMNASMN1; SMN2KMT2A | |
| SCHEMBL8057954 | 0.74 | HTT (0.61) | MAPTHTTLMNASMN1; SMN2KMT2A | |
| SCHEMBL3688848 | 0.73 | MAPT (0.47) | MAPTHTTMITFKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204420-A1 | For therapy of diseases and disorders associated with unwanted or aberrant gene expression | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-10-14 | — | — | US | claimed |
| WO-2004043417-A2 | COMPOSITION FOR DYEING KERATIN FIBRES CONTAINING A DYE PRECURSOR AND AN ENZYME WITH NITROREDUCTASE ACTIVITY | L'OREAL (FR) | 2004-05-27 | — | — | WO | claimed |
| WO-2004042002-A2 | COMPOUNDS FOR MODULATING RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-05-21 | — | — | WO | claimed |
| CN-110157722-B | Recombinant strain and construction method and application thereof | 廊坊梅花生物技术开发有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-118206555-B | 3, 8-Disubstituted adenine derivative, preparation method and application thereof | 海赋药业(海南)有限责任公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118206555-A | 3, 8-Disubstituted adenine derivative, preparation method and application thereof | 海赋药业(海南)有限责任公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118084914-A | Synthesis method of medicinal adenine phosphate | 天津力生制药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112574176-B | Heteroaryl compound and application thereof | 隆泰申医药科技(南京) 有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-115443277-A | Compounds as kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-209305612-U | A kind of adenine transport vehicle that protectiveness is strong | 江西诚志生物工程有限公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-209302738-U | Mixing arrangement is used in a kind of production of adenine | 江西诚志生物工程有限公司 | 2019-08-27 | — | — | CN | disclosed |
| WO-2004002990-A2 | SYNTHESIS OF PURINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| EP-0126935-B1 | HYDROCARBON OXIDATE COMPOSITION | ASHLAND OIL, INC. (US) | 1987-10-07 | — | — | EP | disclosed |
| US-4491535-A | LUBRICANTS, GREASES, OLEFIN COPOLYMER, DIAMINE BLEND | ASHLAND OIL, INC. (US) | 1985-01-01 | — | — | US | disclosed |
| EP-0126935-A1 | Hydrocarbon oxidate composition | ASHLAND OIL, INC. (US) | 1984-12-05 | — | — | EP | disclosed |
| US-4388244-A | REACTION PRODUCT WITH POLYAMINE; CORROSION INHIBITOR | ASHLAND OIL, INC. (US) | 1983-06-14 | — | — | US | disclosed |
| EP-0068199-A1 | Petroleum or hydrocarbon wax oxidate composition | ASHLAND OIL, INC. (US) | 1983-01-05 | — | — | EP | disclosed |
| US-4055411-A | 5-NITRO-PYRIMIDINES | CIBA-GEIGY CORPORATION (US) | 1977-10-25 | — | — | US | disclosed |
| US-4014677-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-3948914-A | PLANT GROWTH REGULATORS | CIBA-GEIGY CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204420-A1 | For therapy of diseases and disorders associated with unwanted or aberrant gene expression | SNRPE, L3MBTL1, ATF4 | MAPT 2205/4885HTT 247/4885MITF 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.